<DOC>
	<DOCNO>NCT00853242</DOCNO>
	<brief_summary>The purpose clinical study compare effect Genz-644470 effect placebo sevelamer carbonate ( RenvelaÂ® ) reduction serum phosphorus hyperphosphatemic chronic kidney disease participant hemodialysis .</brief_summary>
	<brief_title>Randomized Study Comparing Genz-644470 , Placebo , Sevelamer Carbonate Chronic Kidney Disease Patients Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Serum phosphate level great ( &gt; ) 5.5 milligram per deciliter ( mg/dL ) ( 1.78 millimole per liter [ mmol/L ] ) discontinuation current phosphate binder therapy Men woman 18 year old Have active dysphagia swallow disorder predisposition current bowel obstruction , ileus , severe gastrointestinal motility disorder include severe constipation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Phosphate Binder</keyword>
	<keyword>Phosphate</keyword>
	<keyword>Hyperphosphatemia</keyword>
</DOC>